Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

详细信息    查看全文

• 作者：Chris J Bushe ; Deborah Falk ; Ernie Anand ; Marta Casillas ; Elena Perrin…
• 关键词：Depot antipsychotic ; Olanzapine ; Olanzapine long ; acting injection ; Olanzapine pamoate ; Post ; injection delirium/sedation syndrome ; Schizophrenia
• 刊名：BMC Psychiatry
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：568 KB
• 参考文献：1. Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX, Korhonen, P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: pp. 603-9 CrossRef
  2. Velligan, DI, Weiden, PJ, Sajatovic, M, Scott, J, Carpenter, D, Ross, R (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70: pp. 1-46
  3. Kane, JM, Detke, HC, Naber, D, Sethuraman, G, Lin, DY, Bergstrom, RF (2010) Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167: pp. 181-9 CrossRef
  4. Lauriello, J, Lambert, T, Andersen, S, Lin, D, Taylor, CC, McDonnell, D (2008) An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 69: pp. 790-9 CrossRef
  5. McDonnell, D, Andersen, S, Detke, H, Zhao, F, Watson, S (2011) Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights: Psychiatry 3: pp. 37-47 CrossRef
  6. Detke, HC, McDonnell, DP, Brunner, E, Zhao, F, Sorsaburu, S, Stefaniak, VJ (2010) Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. I: analysis of cases. BMC Psychiatry 10: pp. 43 CrossRef
  Zyprexa Relprevv United States Prescribing Information.
  7. European Medicines Agency. Summary of product characteristics for ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection. 2014. [https://www.medicines.org.uk/emc/medicine/21361] (Accessed 26 March, 2015).
  8. McDonnell, DP, Detke, HC, Bergstrom, RF, Kothare, P, Johnson, J, Stickelmeyer, M (2010) Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. II: investigations of mechanism. BMC Psychiatry 10: pp. 45 CrossRef
  9. Cummings, JL, Barritt, CF, Horan, M (1987) Delusions induced by procaine penicillin: case report and review of the syndrome. Int J Psychiatry Med 116: pp. 163-8
  10. Downham, TF, Cawley, RA, Salley, SO, Dal Santo, G (1978) Systemic toxic reactions to procaine penicillin G. Sex Transm Dis 5: pp. 4-9 CrossRef
  11. Institute for Safe Medication Practices. ISMP medication safety alert: action needed to prevent serious tissue injury with IV promethazine. 2006. [http://www.ismp.org/Newsletters/acutecare/articles/20060810.asp] (Accessed 26 March, 2015).
  12. Sen, S, Chini, EN, Brown, MJ (2005) Complications after unintentional intra-arterial injection of drugs: risks, outcomes, and management strategies. Mayo Clin Proc 80: pp. 783-95 CrossRef
  13. US Food and Drug Administration. FDA drug safety communication: FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate). Safety Announcement. 2013. [http://www.fda.gov/drugs/drugsafety/ucm356971.htm] (Accessed 26 March, 2015).
  14. Flanagan, RJ (2008) Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 23: pp. 43-51 CrossRef
  15. Saar, E, Beyer, J, Gerostamoulos, D, Drummer, OH (2012) The time-dependant post-mortem redistribution of antipsychotic drugs. Forensic Sci Int 222: pp. 223-7 CrossRef
  16. McDonnell, DP, Detke, HC, Falk, DM, Shatapath
• 刊物主题：Psychiatry; Psychotherapy;
• 出版者：BioMed Central
• ISSN：1471-244X

文摘

Background Olanzapine long-acting injection (LAI) for the treatment of schizophrenia was associated with a cluster of symptoms termed post-injection delirium/sedation syndrome (PDSS) in a small percentage (~2%) of patients during clinical trials. The objective of this analysis was to evaluate the rate and clinical characteristics of PDSS since olanzapine LAI entered commercial use. Methods Cases of PDSS were identified from all reported adverse events during worldwide commercial use of olanzapine LAI through to 1 March 2014. Data sources included two ongoing post-marketing safety studies as well as spontaneously reported adverse events from routine clinical practice over a 5-year period (1 March 2009 to 1 March 2014). Results A total of 338 PDSS events were identified. Of these, 91% occurred within 1 hour of injection, and 52% of these occurred within 15 minutes. None of the PDSS events in this analysis were fatal, and most resolved within 72 hours. The most common symptoms (occurring in >30% of cases) were sedation (61%), confusion (56%), dysarthria (54%), somnolence (46%), dizziness (45%) and disorientation (35%). Overall, PDSS occurred with approximately 0.07% of injections and in 0.46-.03% of patients (reporting and incidence rates from spontaneous reports and post-marketing safety studies, respectively). Conclusions The PDSS events reported during routine clinical use of olanzapine LAI are generally similar in incidence and presentation to those reported in clinical trials. Caution should be applied when interpreting spontaneously reported rates of adverse events, however, due to potential under-reporting. Implemented risk-minimisation activities may contribute substantially to the identification and appropriate management of patients with PDSS in clinical practice.